Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
Shares of BioChryst Pharmaceuticals (NASDAQ: BCRX) jumped 14.7% this week, according to data from S&P Global Market Intelligence. The stock opened Monday at $10.40 a share and climbed to its weekly high at $12.76 on Wednesday. The stock has a 52-week low of $10.13 and a 52-week high of $19.99.
Image source: Getty Images.
BioChryst focuses on oral small-molecule enzyme therapies to treat rare diseases. The company has two marketed therapies, Orladeyo (berotralstat) and Rapivab (peramivir). Orladeyo is used to prevent attacks of hereditary angioedema, a type of swelling in the deeper layers of skin, often around the face and lips, in adults and children 12 years of age and older. Rapivab is a flu antiviral. BioChryst also has several ongoing drugs in trials.
Source Fool.com
